Advertisement

Leflunomide Tablets

[20 September 2016]

Products Affected - Description

Leflunomide tablet, Apotex
10 mg, 30 count (NDC 60505-2502-01)
20 mg, 30 count (NDC 60505-2503-01)
 
Leflunomide tablet, Heritage
10 mg, 30 count (NDC 23155-0043-03)
20 mg, 30 count (NDC 23155-0044-03)

Reason for the Shortage

  • Apotex did not provide a reason for the shortage.
  • Heritage states the shortage is due to a delay in obtaining active ingredient.
  • Sanofi-Aventis has Arava available.
  • Winthrop has leflunomide tablets available.
  • Trigen has leflunomide tablets available.

Available Products

Arava tablet, Sanofi-Aventis
10 mg, 30 count (NDC 00088-2160-30)
20 mg, 30 count (NDC 00088-2161-30)
 
Leflunomide tablet, Trigen
10 mg, 30 count (NDC 13811-0677-30)
20 mg, 30 count (NDC 13811-0678-30)
 
Leflunomide tablet, Winthrop
10 mg, 30 count (NDC 00955-1735-30)
20 mg, 30 count (NDC 00955-1737-30)

Estimated Resupply Dates

  • Apotex has leflunomide 10 mg and 20 mg tablets on allocation.
  • Heritage has leflunomide 10 mg and 20 mg tablets on tight allocation.

Updated

September 20 and 13, June 16, April 8, March 2, January 27, 2016; December 16, September 21, August 20, July 14, 8 and 2, May 18, April 24 and 22, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing